Replies to post #133194 on Biotech Values

[mcbio]

IMO I think the sales growth in Promacta should continue to accelerate well into next year! I suspect the dropping of the REMS should be a big plus.

Do we have other examples we can readily look at where a REMS has been dropped and the subsequent impact on sales of the drug(s) in question? I would think that would be a helpful exercise. Also, why does Promacta have a REMS in the first place? I thought a REMS was reserved for drugs with side effect issues or at least a somewhat questionable risk/benefit profile. What are the specifics as it relates to Promacta?